Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine

Journal of the American Academy of Dermatology

Volumn 35, Issue 5 I, 1996, Pages 783-785

  Caplan, Steven E ^a   Kauffman, C Lisa ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CASE REPORT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INTRALESIONAL DRUG ADMINISTRATION; MALE; MELANOMA; PRIORITY JOURNAL; SKIN TUBERCULOSIS;

EID: 0029968983     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90753-7     Document Type: Article

References (16)

1. Morton DL, Eilber FR, Malmgren RA, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-64.
2. Nathanson L. Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 1972;56:659-65.
3. Pinsky C, Hisschant G, Oettgen H. Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr 1973;39:225-8.
4. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection and control. Washington, (DC): American Society for Microbiology, 1994:531-57.
5. Lotte A, Wasz-Hockert O, Poisson N, et al. BCG complications: estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984;21:107-93.
6. Elias G. Adjuvant immunotherapy in patients with melanoma: a new approach. Maryland Med J 1990;39:634.
7. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guérin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-90.
8. Dostrovsky A, Sagher F. Dermatologic complications of BCG vaccination. Br J Dermatol 1963;75:181-92.
9. Tappeiner G, Wolff K. Tuberculosis and other mycobacterial infections. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, editors. Dermatology in general medicine. 4th ed. New York: McGraw-Hill, 1993:2370-95.
10. Shea CR, Imber MJ, Cropley TG, et al. Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma. J Am Acad Dermatol 1989;21:1119-22.
11. Sparks FC. Hazards and complications of BCG immunotherapy. Med Clin North Am 1976;60:499-509.
12. Aungst CW, Sokal JE, Jager BV. Complications of BCG vaccination in neoplastic disease. Ann Intern Med 1975; 82:666-9.
13. Hatzitheofilou C, Obenchain DF, Porter DD, et al. Granulomas in melanoma patients treated with BCG immunotherapy. Cancer 1982;49:55-60.
14. Rosenberg EB, Kanner SP, Schwartzman RJ, et al. Systemic infection following BCG therapy. Arch Intern Med 1974;134:769-70.
15. Briggs PC, Heckler FR. Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma. Plast Reconstr Surg 1988;81:952-3.
16. Brown FS, Anderson RH, Burnett JW. Cutaneous tuberculosis. J Am Acad Dermatol 1982;6:101-6.